Company CNS Pharmaceuticals, Inc.

Equities

CNSP

US18978H2013

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 02:00:00 27/04/2024 am IST			5-day change	1st Jan Change
0.215 ^USD	+5.39%		+6.44%	-83.07%

23/04	Transcript : CNS Pharmaceuticals, Inc. - Special Call
01/04	CNS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

CNS Pharmaceuticals Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system (CNS). The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is in development for the treatment of a number of serious brain and CNS oncology indications, including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. In addition, the Company is advancing the development of its WP1244/WP1874 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents. The Company is also evaluating the use of WP1244/WP1874 in the treatment of other primary brain and central nervous system cancers, as well as cancers metastatic to the brain including pancreatic, ovarian, and lymphomas.

Number of employees: 4

Managers	Title	Age	Since
John Climaco CEO	Chief Executive Officer	55	01/17/01
Christopher Downs DFI	Director of Finance/CFO	45	13/19/13
Sandra Silberman CTO	Chief Tech/Sci/R&D Officer	69	01/17/01
Donald Picker CTO	Chief Tech/Sci/R&D Officer	78	01/18/01

Members of the board	Title	Age	Since
Donald Picker CTO	Chief Tech/Sci/R&D Officer	78	01/18/01
John Climaco CEO	Chief Executive Officer	55	01/17/01
Faith Charles CHM	Chairman	62	03/23/03
Jeffry Keyes BRD	Director/Board Member	51	25/18/25
Bettina Cockroft BRD	Director/Board Member	57	08/23/08
Jerzy Gumulka BRD	Director/Board Member	75	08/17/08
Carl Evans BRD	Director/Board Member	77	09/18/09
Amy Mahery BRD	Director/Board Member	-	18/01

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	10,634,932	9,621,176 ( 90.47 %)	0	90.47 %

Name	Equities	%	Valuation
John Climaco 2.558 %	215,676	2.558 %	78 075 $
Armistice Capital LLC 1.447 %	122,000	1.447 %	44 164 $
Christopher Downs 1.227 %	103,438	1.227 %	37 445 $
Smith Anglin Financial LLC 1.072 %	90,332	1.072 %	32 700 $
Vanguard Group, Inc. (Subfiler) 0.6924 %	58,369	0.6924 %	21 130 $
Jerzy Gumulka 0.5101 %	43,006	0.5101 %	15 568 $
Carl Evans 0.3969 %	33,458	0.3969 %	12 112 $
Geode Capital Management LLC 0.2899 %	24,436	0.2899 %	8 846 $
STATE STREET CORPORATION 0.2676 %	22,556	0.2676 %	8 165 $
FSM Wealth Advisors LLC 0.2264 %	19,084	0.2264 %	6 908 $

CNS Pharmaceuticals, Inc.

2100 West Loop South Suite 900

77027, Houston

http://www.cnspharma.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
CNS PHARMACEUTICALS, INC.	-83.07%	2.29M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research